ACRV - Latest News
Acrivon Therapeutics, Inc. Common Stock (ACRV), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $50.5M. Beta to the broader market is 2.02.
The article list below shows the most recent ACRV headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ACRV Headlines
Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit
globenewswire.com - May 21, 2026
WATERTOWN, Mass. , May 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc.
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - May 15, 2026
WATERTOWN, Mass. , May 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc.
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
globenewswire.com - May 13, 2026
The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (bi
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
globenewswire.com - Apr 17, 2026
Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy of AC
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - Apr 15, 2026
WATERTOWN, Mass. , April 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc.
How News Affects ACRV Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ACRV's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ACRV news questions
- What is the latest ACRV news headline?
- The most recent ACRV headline (May 21, 2026) is "Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ACRV news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ACRV news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ACRV options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.